Peptide Knowledge Base · Metabolic

Survodutide: what it is, what the evidence says, and its real status

A dual agonist whose differentiator is the liver, it is being studied in MASH as well as weight.

Can you actually get it?

Plain-English verdict: Education only.

Regulatory status: Investigational (Phase 3).

How does Survodutide work?

A dual agonist at GLP-1 and glucagon receptors; the glucagon arm adds energy expenditure and a direct hepatic effect studied in liver disease.

What it does — and what it does not do

What it does: Studied for weight reduction and for improvement of MASH (metabolic-associated steatohepatitis).

What it does not do: It is not approved, not available, and not a liver treatment you can obtain; the MASH data is trial-stage.

How honest is the evidence?

Evidence grade B — Good human evidence.

Phase-2 MASH data; Phase-3 ongoing, re-verify

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Long-term outcomes and the MASH benefit are still being established in Phase-3.

WADA status: Not prohibited.

How it is taken

What the literature reports: subcutaneous, weekly, titrated. Educational only, no dose figures.

Who should not take it

Investigational, safety not fully characterized; clinician-gated.

Sources

Survodutide Phase-2 MASH (NEJM 2024) · SYNCHRONIZE Phase-3 (ongoing, re-verify)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.